Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function-Reference-Cited by-同舟云学术

Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function

Published:2020-09 Issue: Volume:171 Page:106073
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Salvatore Donatello,Terlizzi Vito,Francalanci Michela,Taccetti Giovanni,Messore Barbara,Biglia Carlotta,Pisi Giovanna,Calderazzo Maria Adelaide,Caloiero Mimma,Pizzamiglio Giovanna,Majo Fabio,Cresta Federico,Leonetti Giuseppina,De Venuto Domenica

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference28 articles.

1. Cystic fibrosis;Elborn;Lancet,2016

2. Cystic fibrosis;Rowe;N. Engl. J. Med.,2005

3. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis;De Boeck;J. Cyst. Fibros.,2014

4. Patients with cystic fibrosis having a residual function mutation: data from the Italian registry;Salvatore;Pediatr. Pulmonol.,2019

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians;Current Problems in Pediatric and Adolescent Health Care;2024-06

2. One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis;Heliyon;2024-03

3. Identification and in silico structural analysis for the first de novo mutation in the cystic fibrosis transmembrane conductance regulator protein in Iran: case report and developmental insight using microsatellite markers;Therapeutic Advances in Respiratory Disease;2024-01

4. Use of CFTR modulators in special populations, part 2: Severe lung disease;Pediatric Pulmonology;2023-09-20

5. Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators;Current Opinion in Pulmonary Medicine;2023-08-23